MSN Laboratories gets USFDA approval for febuxostat tablets

Novadoz Pharmaceuticals, the US based sales & marketing affiliate for MSN Labs has received USFDA approval for their generic version of febuxostat 40mg and 80mg tablets.

Febuxostat is a xanthine oxidase inhibitor is indicated for the chronic management of hyperuricemia (elevated levels of uric acid) in adult patients with gout who have a poor response to a maximally titrated dose of Allopurinol.

According to market estimates, the sales figure for a period of 12 months is around US$ 430 million.

Company Profile : MSN Laboratories Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.